News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

National Institute for Clinical Excellence (NICE) Turns Down Biogen Idec, Inc. (Massachusetts) (BIIB)'s Oral MS Drug


2/21/2014 7:31:34 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The National Institute for Health and Care Excellence (NICE) has rejected the routine use of Biogen Idec's oral multiple sclerosis (MS) treatment Tecfidera in draft guidance. NICE, which assesses the value of drugs for use on the NHS in England and Wales, said that Tecfidera (dimethyl fumarate) was not a cost-effective use of NHS resources to treat adults with relapsing-remitting MS; when used as recommended a year's treatment costs more than Ā£16,000.

Help employers find you! Check out all the jobs and post your resume.


Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES